TABLE 1.

Quality of life and biochemical characteristics of patients pre- and post-MARS therapy

	Patient			Fold change, mean
	1	2	3
Diagnosis	PBC	PBC	BRIC
MELD score	11	7	20
EQ-5D score (VAS)				5.33↑
Pre	10	20	20
Post	90	70	70
Bile acids, μmol/L				5.43↓
Pre	555.1	531.5	350.1
Post	48.2	169.1	51.8
Ammonia, μmol/L				1.11↑
Pre	24	44	27
Post	42	37	20
Alanine aminotransferase, U/L				1.05↑
Pre	151	42	59
Post	152	46	62
Aspartate aminotransferase, U/L				1.12↑
Pre	173	56	69
Post	159	65	88
Total bilirubin, μmol/L				1.48↓
Pre	208	28	565
Post	138	23	303
Conjugated bilirubin, μmol/L				1.69↓
Pre	125	14	377
Post	79	10	161
Alkaline phosphatase, U/L				1.11↓
Pre	481	255	532
Post	445	239	448
Gamma-glutamyl transpeptidase, U/L				1.18↓
Pre	73	212	51
Post	60	190	42
International normalized ratio				1.07↑
Pre	1.1	1	1.7
Post	1	1	2.2
Partial thromboplastin time, s				2.26↑
Pre	31	31	55
Post	57	126	48
Hemoglobin, g/L				1.11↓
Pre	96	98	106
Post	81	91	98
Platelets, ×109/L				1.30↓
Pre	199	114	271
Post	148	81	231
Creatinine, μmol/L				1.26↓
Pre	47	80	47
Post	45	63	30
Urea, mmol/L				2.94↓
Pre	4.4	5.2	2.6
Post	1.1	2	<1.0

Fold-changes are given, with arrows representing fold-change increase (↑) or decrease (↓). BRIC Benign recurrent intrahepatic cholestasis; EQ-5D European Quality of Life-5 Dimensions questionnaire; MARS Molecular adsorbent recirculating system; MELD Model for End-stage Liver Disease; PBC Primary biliary cirrhosis; VAS Visual analogue score